An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE)

被引：8
|
作者：
Machiels, J. H.
Subramanian, S.
Ruzsa, A.
Repassy, G.
Lifrenko, I.
Flygare, A.
Sorensen, P.
Ehrnrooth, E.
Baadsgaard, O.
Clement, P. M.
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[2] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[3] Zala Megyei Korhaz, Onkol Osztaly, Zalaegerszeg Pozva, Hungary
[4] Semmelweis Univ, H-1085 Budapest, Hungary
[5] Kursk Reg Oncol Dispencary, Kursk, Russia
[6] Genmab, Copenhagen, Denmark
[7] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[8] Catholic Univ Louvain, B-3000 Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 18期
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba5506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5506
引用
收藏
页数：1
相关论文
共 27 条
  • [21] A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN).
    Bastholt, L
    Specht, L
    Jensen, K
    Brun, E
    Loft, A
    Petersen, J
    Kastberg, H
    Eriksen, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 507S - 507S
  • [22] A global phase Ill multicenter, randomized, double arm, open label trial of ASP-1929 photoimmunotherapy versus physician's choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
    Biel, Merrill A.
    Gillenwater, Ann M.
    Cognetti, David M.
    Johnson, Jennifer Maria
    Argiris, Athanassios
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
    Felip, Enriqueta
    Hirsh, Vera
    Popat, Sanjay
    Cobo, Manuel
    Fulop, Andrea
    Dayen, Charles
    Trigo, Jose M.
    Gregg, Richard
    Waller, Cornelius F.
    Soria, Jean-Charles
    Goss, Glenwood D.
    Gordon, James
    Wang, Bushi
    Palmer, Michael
    Ehrnrooth, Eva
    Gadgeel, Shirish M.
    CLINICAL LUNG CANCER, 2018, 19 (01) : 74 - +
  • [24] An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial
    Gelsomino, F.
    Tiseo, M.
    Boni, L.
    Cavanna, L.
    Camerini, A.
    Chiari, R.
    Verusio, C.
    Tognetto, M.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] A Phase IIb, 4 Arm Open-label, Randomized Trial, to Assess the Safety and Efficacy of Concurrent hR3 Monoclonal Antibody against EGF-receptor with Chemoradiation Therapy or with Radiation Therapy in Patients with Advanced (Stage III-IVa), Inoperable Head and Neck Cancer
    Viswanath, L.
    Reddy, K. B. K. M.
    Vidyasagar, M.
    Koteshwar, R.
    Shenoy, A. M.
    Thimmaiah, N.
    Babu, G.
    Joseph, B.
    Bapsy, P. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S15 - S16
  • [26] Phase Ell, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST)
    Douillard, J. Y.
    Kim, E. S.
    Hirsh, V.
    Mok, T.
    Socinski, M.
    Gervais, R.
    Wu, L. Y.
    Li, L.
    Sellers, M.
    Lowe, E.
    EJC SUPPLEMENTS, 2007, 5 (06): : 2 - 2
  • [27] An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
    Gelsomino, Francesco
    Boni, Luca
    Tiseo, Marcello
    Ricciardi, Serena
    Rocco, Danilo
    Cortinovis, Diego L.
    Proietto, Manuela
    Cogoni, Alessio
    Pasello, Giulia
    Camerini, Andrea
    Sperandi, Francesca
    Colantonio, Ida
    Metro, Giulio
    Mazzoni, Francesca
    Baldini, Editta
    Veccia, Antonello
    Bennicelli, Elisa
    Bettini, Anna Cecilia
    Tognetto, Michele
    LUNG CANCER, 2025, 199
123